BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 20036196)

  • 1. Pathogenesis of Parkinson's disease: emerging role of molecular chaperones.
    Bandopadhyay R; de Belleroche J
    Trends Mol Med; 2010 Jan; 16(1):27-36. PubMed ID: 20036196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.
    Ebrahimi-Fakhari D; Saidi LJ; Wahlster L
    Acta Neuropathol Commun; 2013 Dec; 1(1):79. PubMed ID: 24314025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular chaperones in Parkinson's disease--present and future.
    Ebrahimi-Fakhari D; Wahlster L; McLean PJ
    J Parkinsons Dis; 2011; 1(4):299-320. PubMed ID: 22279517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders.
    Padilla-Godínez FJ; Ramos-Acevedo R; Martínez-Becerril HA; Bernal-Conde LD; Garrido-Figueroa JF; Hiriart M; Hernández-López A; Argüero-Sánchez R; Callea F; Guerra-Crespo M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein misfolding and aggregation in Parkinson's disease.
    Tan JM; Wong ES; Lim KL
    Antioxid Redox Signal; 2009 Sep; 11(9):2119-34. PubMed ID: 19243238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular chaperones and co-chaperones in Parkinson disease.
    Dimant H; Ebrahimi-Fakhari D; McLean PJ
    Neuroscientist; 2012 Dec; 18(6):589-601. PubMed ID: 22829394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implication.
    Dohm CP; Kermer P; Bähr M
    Neurodegener Dis; 2008; 5(6):321-38. PubMed ID: 18309232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular chaperones and Parkinson's disease.
    Hu S; Tan J; Qin L; Lv L; Yan W; Zhang H; Tang B; Wang C
    Neurobiol Dis; 2021 Dec; 160():105527. PubMed ID: 34626793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein degradation pathways in Parkinson's disease: curse or blessing.
    Ebrahimi-Fakhari D; Wahlster L; McLean PJ
    Acta Neuropathol; 2012 Aug; 124(2):153-72. PubMed ID: 22744791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases.
    Luo GR; Le WD
    Curr Pharm Biotechnol; 2010 Feb; 11(2):180-7. PubMed ID: 20166963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.
    Sharma SK; Priya S
    Cell Mol Life Sci; 2017 Feb; 74(4):617-629. PubMed ID: 27522545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease.
    Hinault MP; Farina-Henriquez-Cuendet A; Goloubinoff P
    Neurodegener Dis; 2011; 8(6):397-412. PubMed ID: 21411979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of chaperones in Parkinson's disease and prion diseases.
    Winklhofer KF; Tatzelt J
    Handb Exp Pharmacol; 2006; (172):221-58. PubMed ID: 16610362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the Role of Ubiquitin-Proteasome System in Parkinson's Disease.
    Behl T; Kumar S; Althafar ZM; Sehgal A; Singh S; Sharma N; Badavath VN; Yadav S; Bhatia S; Al-Harrasi A; Almoshari Y; Almikhlafi MA; Bungau S
    Mol Neurobiol; 2022 Jul; 59(7):4257-4273. PubMed ID: 35505049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone.
    Lee JS; Kanai K; Suzuki M; Kim WS; Yoo HS; Fu Y; Kim DK; Jung BC; Choi M; Oh KW; Li Y; Nakatani M; Nakazato T; Sekimoto S; Funayama M; Yoshino H; Kubo SI; Nishioka K; Sakai R; Ueyama M; Mochizuki H; Lee HJ; Sardi SP; Halliday GM; Nagai Y; Lee PH; Hattori N; Lee SJ
    Brain; 2019 Sep; 142(9):2845-2859. PubMed ID: 31312839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase 6 regulates cytotoxic α-synuclein accumulation through induction of the heat shock response.
    Du Y; Wang F; Zou J; Le W; Dong Q; Wang Z; Shen F; Yu L; Li Y
    Neurobiol Aging; 2014 Oct; 35(10):2316-28. PubMed ID: 24866403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
    Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
    J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis.
    Xilouri M; Vogiatzi T; Vekrellis K; Stefanis L
    Autophagy; 2008 Oct; 4(7):917-9. PubMed ID: 18708765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue of α-synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking.
    Stojkovska I; Wani WY; Zunke F; Belur NR; Pavlenko EA; Mwenda N; Sharma K; Francelle L; Mazzulli JR
    Neuron; 2022 Feb; 110(3):436-451.e11. PubMed ID: 34793693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.